51
|
Martínez-Reyes I, Cuezva JM. The H+-ATP synthase: A gate to ROS-mediated cell death or cell survival. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS 2014; 1837:1099-112. [DOI: 10.1016/j.bbabio.2014.03.010] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 03/03/2014] [Accepted: 03/19/2014] [Indexed: 12/13/2022]
|
52
|
San Martín A, Sotelo-Hitschfeld T, Lerchundi R, Fernández-Moncada I, Ceballo S, Valdebenito R, Baeza-Lehnert F, Alegría K, Contreras-Baeza Y, Garrido-Gerter P, Romero-Gómez I, Barros LF. Single-cell imaging tools for brain energy metabolism: a review. NEUROPHOTONICS 2014; 1:011004. [PMID: 26157964 PMCID: PMC4478754 DOI: 10.1117/1.nph.1.1.011004] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2014] [Revised: 04/09/2014] [Accepted: 04/10/2014] [Indexed: 05/03/2023]
Abstract
Neurophotonics comes to light at a time in which advances in microscopy and improved calcium reporters are paving the way toward high-resolution functional mapping of the brain. This review relates to a parallel revolution in metabolism. We argue that metabolism needs to be approached both in vitro and in vivo, and that it does not just exist as a low-level platform but is also a relevant player in information processing. In recent years, genetically encoded fluorescent nanosensors have been introduced to measure glucose, glutamate, ATP, NADH, lactate, and pyruvate in mammalian cells. Reporting relative metabolite levels, absolute concentrations, and metabolic fluxes, these sensors are instrumental for the discovery of new molecular mechanisms. Sensors continue to be developed, which together with a continued improvement in protein expression strategies and new imaging technologies, herald an exciting era of high-resolution characterization of metabolism in the brain and other organs.
Collapse
Affiliation(s)
- Alejandro San Martín
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Tamara Sotelo-Hitschfeld
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Rodrigo Lerchundi
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Ignacio Fernández-Moncada
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Sebastian Ceballo
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
| | - Rocío Valdebenito
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
| | | | - Karin Alegría
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
| | - Yasna Contreras-Baeza
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Pamela Garrido-Gerter
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - Ignacio Romero-Gómez
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Universidad Austral de Chile, Valdivia, Chile
| | - L. Felipe Barros
- Centro de Estudios Científicos, Arturo Prat 514, Valdivia, 5110466, Chile
- Address all correspondence to: L. Felipe Barros, E-mail:
| |
Collapse
|
53
|
Chen WW, Birsoy K, Mihaylova MM, Snitkin H, Stasinski I, Yucel B, Bayraktar EC, Carette JE, Clish CB, Brummelkamp TR, Sabatini DD, Sabatini DM. Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells. Cell Rep 2014; 7:27-34. [PMID: 24685140 PMCID: PMC4040975 DOI: 10.1016/j.celrep.2014.02.046] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2013] [Revised: 02/07/2014] [Accepted: 02/28/2014] [Indexed: 01/19/2023] Open
Abstract
Mitochondrial respiratory chain disorders are characterized by loss of electron transport chain (ETC) activity. Although the causes of many such diseases are known, there is a lack of effective therapies. To identify genes that confer resistance to severe ETC dysfunction when inactivated, we performed a genome-wide genetic screen in haploid human cells with the mitochondrial complex III inhibitor antimycin. This screen revealed that loss of ATPIF1 strongly protects against antimycin-induced ETC dysfunction and cell death by allowing for the maintenance of mitochondrial membrane potential. ATPIF1 loss protects against other forms of ETC dysfunction and is even essential for the viability of human ρ° cells lacking mitochondrial DNA, a system commonly used for studying ETC dysfunction. Importantly, inhibition of ATPIF1 ameliorates complex III blockade in primary hepatocytes, a cell type afflicted in severe mitochondrial disease. Altogether, these results suggest that inhibition of ATPIF1 can ameliorate severe ETC dysfunction in mitochondrial pathology.
Collapse
Affiliation(s)
- Walter W Chen
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Kivanc Birsoy
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Maria M Mihaylova
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Harriet Snitkin
- Department of Cell Biology, New York University School of Medicine, New York, New York, 10016, USA
| | - Iwona Stasinski
- Department of Cell Biology, New York University School of Medicine, New York, New York, 10016, USA
| | - Burcu Yucel
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Erol C Bayraktar
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
| | - Jan E Carette
- Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Clary B Clish
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
| | - Thijn R Brummelkamp
- Department of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, The Netherlands
| | - David D Sabatini
- Department of Cell Biology, New York University School of Medicine, New York, New York, 10016, USA
| | - David M Sabatini
- Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142, USA
- Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA 02139, USA
- Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, USA
- David H. Koch Institute for Integrative Cancer Research at MIT, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
- Howard Hughes Medical Institute, MIT, Cambridge, MA 02139, USA
| |
Collapse
|
54
|
Formentini L, Pereira MP, Sánchez-Cenizo L, Santacatterina F, Lucas JJ, Navarro C, Martínez-Serrano A, Cuezva JM. In vivo inhibition of the mitochondrial H+-ATP synthase in neurons promotes metabolic preconditioning. EMBO J 2014; 33:762-78. [PMID: 24521670 PMCID: PMC4000092 DOI: 10.1002/embj.201386392] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 01/08/2014] [Accepted: 01/13/2014] [Indexed: 12/25/2022] Open
Abstract
A key transducer in energy conservation and signaling cell death is the mitochondrial H(+)-ATP synthase. The expression of the ATPase inhibitory factor 1 (IF1) is a strategy used by cancer cells to inhibit the activity of the H(+)-ATP synthase to generate a ROS signal that switches on cellular programs of survival. We have generated a mouse model expressing a mutant of human IF1 in brain neurons to assess the role of the H(+)-ATP synthase in cell death in vivo. The expression of hIF1 inhibits the activity of oxidative phosphorylation and mediates the shift of neurons to an enhanced aerobic glycolysis. Metabolic reprogramming induces brain preconditioning affording protection against quinolinic acid-induced excitotoxicity. Mechanistically, preconditioning involves the activation of the Akt/p70S6K and PARP repair pathways and Bcl-xL protection from cell death. Overall, our findings provide the first in vivo evidence highlighting the H(+)-ATP synthase as a target to prevent neuronal cell death.
Collapse
Affiliation(s)
- Laura Formentini
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIIIMadrid, Spain
- Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de MadridMadrid, Spain
| | - Marta P Pereira
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
| | - Laura Sánchez-Cenizo
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIIIMadrid, Spain
- Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de MadridMadrid, Spain
| | - Fulvio Santacatterina
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIIIMadrid, Spain
- Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de MadridMadrid, Spain
| | - José J Lucas
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), ISCIIIMadrid, Spain
| | - Carmen Navarro
- Departamento de Patología y Neuropatología, Instituto de Investigación Biomédica de Vigo (IBIV)Vigo, Spain
| | - Alberto Martínez-Serrano
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
| | - José M Cuezva
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM)Madrid, Spain
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIIIMadrid, Spain
- Instituto de Investigación Hospital 12 de Octubre, Universidad Autónoma de MadridMadrid, Spain
| |
Collapse
|
55
|
Sugawara K, Fujikawa M, Yoshida M. Screening of protein kinase inhibitors and knockdown experiments identified four kinases that affect mitochondrial ATP synthesis activity. FEBS Lett 2013; 587:3843-7. [PMID: 24157360 DOI: 10.1016/j.febslet.2013.10.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Accepted: 10/10/2013] [Indexed: 01/23/2023]
Abstract
Mitochondrial ATP synthase, a major ATP supplier in respiring cells, should be regulated in amount and in activity to respond to the varying demands of cells for ATP. We screened 80 protein kinase inhibitors and found that HeLa cells treated with four inhibitors exhibited reduced mitochondrial ATP synthesis activity. Consistently, knockdown of their target kinases (PKA, PKCδ, CaMKII and smMLCK) resulted in a decrease in mitochondrial ATP synthesis activity. Among them, mitochondria of smMLCK-knockdown cells contained only a small amount of ATP synthase, while the α- and β-subunits of ATP synthase were produced normally, suggesting that smMLCK affects assembly (or decay) of ATP synthase.
Collapse
Affiliation(s)
- Kanako Sugawara
- International Cooperative Research Project (ICORP), ATP Synthesis Regulation Project, Japan Science and Technology Agency, Aomi 2-3-6, Tokyo 135-0064, Japan; Department of Molecular Bioscience, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto 603-8555, Japan
| | | | | |
Collapse
|
56
|
Nakamura J, Fujikawa M, Yoshida M. IF1, a natural inhibitor of mitochondrial ATP synthase, is not essential for the normal growth and breeding of mice. Biosci Rep 2013; 33:e00067. [PMID: 23889209 PMCID: PMC3775512 DOI: 10.1042/bsr20130078] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Accepted: 07/24/2013] [Indexed: 11/17/2022] Open
Abstract
IF1 is an endogenous inhibitor protein of mitochondrial ATP synthase. It is evolutionarily conserved throughout all eukaryotes and it has been proposed to play crucial roles in prevention of the wasteful reverse reaction of ATP synthase, in the metabolic shift from oxidative phosphorylation to glycolysis, in the suppression of ROS (reactive oxygen species) generation, in mitochondria morphology and in haem biosynthesis in mitochondria, which leads to anaemia. Here, we report the phenotype of a mouse strain in which IF1 gene was destroyed. Unexpectedly, individuals of this IF1-KO (knockout) mouse strain grew and bred without defect. The general behaviours, blood test results and responses to starvation of the IF1-KO mice were apparently normal. There were no abnormalities in the tissue anatomy or the autophagy. Mitochondria of the IF1-KO mice were normal in morphology, in the content of ATP synthase molecules and in ATP synthesis activity. Thus, IF1 is not an essential protein for mice despite its ubiquitous presence in eukaryotes.
Collapse
Affiliation(s)
- Junji Nakamura
- *Department of Molecular Bioscience, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto 603-8555, Japan
- †International Cooperative Research Project (ICORP) ATP-Synthesis Regulation Project, Japan Science and Technology Agency (JST), 2-3-6 Aomi, Tokyo 135-0064, Japan
| | - Makoto Fujikawa
- †International Cooperative Research Project (ICORP) ATP-Synthesis Regulation Project, Japan Science and Technology Agency (JST), 2-3-6 Aomi, Tokyo 135-0064, Japan
- ‡Department of Biochemistry, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan
| | - Masasuke Yoshida
- *Department of Molecular Bioscience, Kyoto Sangyo University, Kamigamo-Motoyama, Kyoto 603-8555, Japan
- †International Cooperative Research Project (ICORP) ATP-Synthesis Regulation Project, Japan Science and Technology Agency (JST), 2-3-6 Aomi, Tokyo 135-0064, Japan
| |
Collapse
|
57
|
Sánchez-Aragó M, Formentini L, García-Bermúdez J, Cuezva JM. IF1 reprograms energy metabolism and signals the oncogenic phenotype in cancer. Cell Cycle 2012; 11:2963-4. [PMID: 22871729 PMCID: PMC3442896 DOI: 10.4161/cc.21387] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Comment on: Formentini L, et al. Mol Cell 2012; 45:731-42.
Collapse
Affiliation(s)
- María Sánchez-Aragó
- Departamento de Biología Molecular; Centro de Biología Molecular Severo Ochoa; CSIC-UAM; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Centro de Investigación Hospital 12 de Octubre; ISCIII; Universidad Autónoma de Madrid; Madrid, Spain
| | - Laura Formentini
- Departamento de Biología Molecular; Centro de Biología Molecular Severo Ochoa; CSIC-UAM; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Centro de Investigación Hospital 12 de Octubre; ISCIII; Universidad Autónoma de Madrid; Madrid, Spain
| | - Javier García-Bermúdez
- Departamento de Biología Molecular; Centro de Biología Molecular Severo Ochoa; CSIC-UAM; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Centro de Investigación Hospital 12 de Octubre; ISCIII; Universidad Autónoma de Madrid; Madrid, Spain
| | - José M. Cuezva
- Departamento de Biología Molecular; Centro de Biología Molecular Severo Ochoa; CSIC-UAM; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER); Centro de Investigación Hospital 12 de Octubre; ISCIII; Universidad Autónoma de Madrid; Madrid, Spain
| |
Collapse
|